IVD 검사 건수 : 제7판(2025-2030년)

The global in vitro diagnostics (IVD) market continues to expand in 2025, driven by powerful innovations in next-generation sequencing (NGS), microfluidics, and precision medicine that are transforming diagnostics into a more personalized, patient-centric field. "IVD Test Procedure Volumes, 7th Edition (2025-2030)" provides a comprehensive, data-driven analysis of global test volume trends, serving as a critical companion to Kalorama Information's flagship publication, "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 18th Edition (2025-2030)".

Quantifying the Global Testing Landscape

This report delivers an in-depth examination of IVD procedures across major testing categories-including molecular diagnostics, clinical chemistry, immunoassays, hematology, coagulation, microbiology, blood banking, and histology/cytology. It quantifies the number of tests performed, the average cost per procedure, and regional variations across key markets worldwide. With forecasts extending through 2030, the study offers essential insight into test utilization trends, cost dynamics, and evolving regional testing patterns that are shaping the global diagnostics landscape.

Technological Advancements Reshaping Diagnostics

As the IVD industry evolves beyond pandemic-driven demand, new paradigms in self-testing, home-based diagnostics, and point-of-care (POC) solutions are accelerating accessibility and reshaping healthcare delivery. Meanwhile, growth in molecular and cancer diagnostics underscores the sector's pivot toward early detection and non-invasive monitoring through liquid biopsy and genomic testing. These advancements align with the global push toward precision medicine-but also introduce new challenges related to cost, regulation, and equitable access.

Navigating Economic and Regulatory Pressures

This report contextualizes these market drivers within a rapidly changing regulatory and economic environment. With rising scrutiny under the EU's IVDR and FDA's evolving frameworks, manufacturers must navigate complex approval pathways while addressing payer pressures that impact reimbursement and adoption. The balance between technological advancement, affordability, and scalability will define the next stage of IVD growth.

Methodology and Strategic Value

Drawing on Kalorama's proprietary methodologies, this study presents accurate, transparent, and actionable estimates of IVD procedure volumes and revenues-empowering executives, strategists, and investors to benchmark performance, identify growth opportunities, and align product portfolios with emerging diagnostic trends.

An Essential Resource for IVD Decision-Makers

For organizations seeking to understand where the IVD market is headed-and how procedural demand will drive innovation, investment, and access over the next five years-"IVD Test Procedure Volumes, 7th Edition (2025-2030)" is an indispensable resource for strategic decision-making.

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

• IVD PROCEDURE VOLUME ESTIMATE AND FORECAST
  • Figure 1-1: Global IVD Procedure Volumes, 2025 and 2030 (in millions # volume)
• SCOPE & METHODOLOGY

CHAPTER TWO: INTRODUCTION

• SCOPE
• OVERVIEW
• INDUSTRY TRENDS
  • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2025-2030 (in millions # volume; $ million)
• DEMOGRAPHIC TRENDS
  • Global Population and Aging
    • Figure 2-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
    • Figure 2-2: Global Population Distribution, 2022
    • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 [Australia, Brazil, Canada, China, China (Hong Kong SAR), France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, Singapore, South Africa, Spain, Turkey, United Kingdom, United States, World]
  • Workforce Reduction
    • Table 2-3: WHO Model List of Essential In Vitro Diagnostics (EDL)
• INCREASE IN CHRONIC DISEASES
  • Figure 2-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)
• PERSONALIZED MEDICINE
• HIGH-CONSEQUENCE DISEASE THREATS
  • Table 2-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats
  • Tickborne Diseases (TBDs)
  • Zika
  • Chagas
  • IVD Vendors Active in Chagas Diagnostics
  • Dengue
  • Ebola
  • Chikungunya
  • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
  • Marburg
  • Monkeypox
• EMERGING AND EMERGED MARKETS
  • Table 2-5: Developed/Developing Economies, UN Classification*, 2025
  • Figure 2-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
  • Where Are the Best Markets?
    • Table 2-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 [Australia, Brazil, China, France, Germany, Hungary, India, Mexico, Netherlands, Peru, Poland, Romania, Saudi Arabia, South Africa, South Korea, Sweden, Switzerland, Turkey, United Kingdom, United States]
  • Economic Growth and the Expanding Middle Class

CHAPTER THREE: IVD TESTING SEGMENTS

• IVD TESTING TRENDS
  • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
• SEGMENT GROWTH PROJECTIONS
  • Point-of-Care (POC) Testing
  • Clinical Chemistry
  • Immunoassays
  • Mass Spectrometry (Immuno)
  • Molecular Assays
  • Hematology
  • Coagulation
  • Conventional Microbiology
  • Blood Grouping/Typing
  • Histology/Cytology
• SEGMENT PRODUCT SALES
  • Table 3-5: IVD Product Sales including Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-6: IVD Product Sales including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-7: IVD Product Sales excluding Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
  • Table 3-8: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]

CHAPTER FOUR: GLOBAL IVD MARKETS

• GENERAL
  • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2025-2030 (millions) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
  • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2025-2030 (%) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
• NORTH AMERICA
  • United States
  • Canada
• MEXICO, CENTRAL, & SOUTH AMERICA
  • Brazil
  • Mexico
  • Other Central & South America
  • Argentina
  • Chile
  • Colombia
  • Peru
  • Venezuela
  • All Other Countries & Territories
• WESTERN EUROPE
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Other Western Europe
  • Austria
  • Belgium
  • Denmark
  • Finland
  • Greece
  • Ireland
  • Norway
  • Netherlands
  • Portugal
  • Sweden
  • Switzerland
  • All Other Countries & Territories
• EASTERN EUROPE
  • Russia
  • Other Eastern Europe
  • Czech Republic
  • Hungary
  • Poland
  • Romania
  • Ukraine
  • All Other Countries
• ASIA/PACIFIC
  • China
  • Japan
  • Other Asian Countries and Territories
  • Australia
  • Hong Kong
  • India
  • Indonesia
  • Malaysia
  • Pakistan
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • New Zealand
  • All Other Countries & Territories
• MIDDLE EAST
  • Turkey
  • Other Middle East
  • Iran
  • Iraq
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • All Other Countries
• AFRICA
  • Nigeria
  • South Africa
  • All Other Countries & Territories

CHAPTER FIVE: POINT-OF-CARE (POC) PROCEDURES

• SCOPE
• INTRODUCTION
  • Point-of-Care (POC) Testing Overview
• GLOBAL POC PROCEDURE VOLUME BY TEST TYPE
  • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2025-2030
  • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2025-20230
  • Figure 5-1: Regional POC Procedure Volumes including blood glucose tests, 2025 [Europe, Japan, United States, Rest of World]
• POC SELF TESTS
  • Table 5-3: POC Self-Test Procedural Volume, by Type, 2025-2030 (millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
  • Traditional Blood Glucose Monitoring Activities
  • Continuous Blood Glucose Monitoring
  • Pregnancy and Fertility Testing
  • Coagulation Testing
  • Fecal Occult Blood Testing
  • Drugs of Abuse Testing
  • H. pylori Testing
  • HIV Testing
  • Infectious Disease
  • Cholesterol Testing
  • POC Urinalysis Testing
  • Other POC Self-Testing
• POC SELF-TESTING PRODUCT SALES
  • Table 5-4: POC Self-Test Product Sales, by Type, 2025-2030 ($ million) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
• PRICING TRENDS
  • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2025-2030 [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
• POC PROFESSIONAL TESTING
  • Table 5-6: POC Professional Procedural Volume, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
  • POC Professional Blood Glucose Testing Procedures
  • POC Professional Critical Care Testing
  • POC Fertility Testing
  • POC Professional Infectious Disease Testing
  • POC Professional Cardiac Marker Testing
  • POC Professional Cholesterol/Lipid Testing
  • POC Professional Coagulation Testing
  • POC Professional HbA1C Testing
  • POC Professional Hematology Testing
  • POC Professional Fecal Occult Blood Screening
  • POC Professional Drugs of Abuse Testing
  • POC Professional Urinalysis Testing
  • Other POC Professional Testing
• POC IVD PRODUCT SALES
  • Table 5-7: POC Professional IVD Product Sales, by Type, 2025-2030 ($ million) [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
• PRICING TRENDS
  • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

CHAPTER SIX: CLINICAL CHEMISTRY PROCEDURES

• SCOPE
• INTRODUCTION
  • Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
  • Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
• TYPES OF TESTS
  • General Chemistry
  • Enzymes
  • Glucose
  • Lipids
  • Proteins
  • Other Compounds
  • Blood Gases & Electrolytes
  • Urinalysis
• GLOBAL SALES OF CLINICAL CHEMISTRY PRODUCTS
  • Table 6-2: Clinical Chemistry Product Sales, by Type, 2025-2030 ($ million) [Blood Gas Analysis, General Chemistry, Urinalysis]
• PRICING TRENDS
  • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]

CHAPTER SEVEN: IMMUNOASSAY PROCEDURES

• SCOPE
• INTRODUCTION
• LABELING TECHNIQUES
  • Enzyme Immunoassays
  • Chemiluminescent Magnetic Immunoassays (CMIAs)
  • Fluorescence Polarization Immunoassays (FPIAs)
  • Radioimmunoassays (RIAs)
    • Table 7-1: Immunoassay Procedural Volume, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
    • Figure 7-1: Regional Immunoassay Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
• TESTING PROCEDURES & PRODUCT SALES
  • Table 7-2: Immunoassay Product Sales, by Type, 2025-2030 ($ million) [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
  • Cardiac Markers
  • Tumor Markers
  • Autoimmune Conditions
  • Allergy Conditions
  • Thyroid Conditions
  • Proteins
  • Alzheimer's Disease
  • Anemia
  • Fertility Testing
  • Therapeutic Drug Monitoring
  • Vitamin D
  • Diabetes/HbA1c
  • Drugs of Abuse
  • Infectious Diseases
    • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2025-2030 [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
    • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
• INSTRUMENTS
• PRICING TRENDS
  • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]

CHAPTER EIGHT: MOLECULAR TESTING PROCEDURES

• INTRODUCTION
  • Table 8-1: Molecular Assay Procedural Volume, by Type, 2025-2030 (millions) [Molecular - Other, Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Non Cancer, Molecular Histology - Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
  • Figure 8-1: Regional Molecular Assay Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
• TYPES OF TESTS
  • Testing Technologies
  • Infectious Diseases
    • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2025-2030 [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
  • Blood Screening
  • Cancer
  • Transplant Matching
  • Thrombophilia SNPs
  • Inherited Diseases
  • Other Molecular Tests
  • Prenatal
• GLOBAL SALES OF MOLECULAR IVD PRODUCTS
  • Table 8-3: Molecular Assay Product Sales, by Type, 2025-2030 ($ million) [Genetic Testing/Inherited Disease, Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - Cancer, Molecular Histology - Non Cancer, Molecular HPV, Molecular Infectious disease, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Other Molecular, Prenatal]
  • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
• PRICING TRENDS
  • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2025-2030 [Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - cancer, Molecular Histology - non cancer, Molecular HPV, Molecular Infectious disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Prenatal]

CHAPTER NINE: LABORATORY-BASED HEMATOLOGY PROCEDURES

• SCOPE
• INTRODUCTION
  • Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
  • Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
• TYPES OF TESTS
• GLOBAL SALES OF HEMATOLOGY PRODUCTS
  • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2025-2030 ($ million) [Complete Blood Count, Other Hematology Tests]
• PRICING TRENDS
  • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]

CHAPTER TEN: COAGULATION TESTING PROCEDURES

• INTRODUCTION
  • Table 10-1: Coagulation Procedural Volume, 2025-2030 [D-dimer, PT/INR]
  • Figure 10-1: US/ROW Coagulation Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
• TYPES OF TESTS
• GLOBAL SALES OF COAGULATION PRODUCTS
  • Table 10-2: Coagulation Product Sales, 2025-2030 ($ million) (D-dimer, PT/INR)
• PRICING TRENDS
  • Table 10-3: Coagulation $ Products per Procedure, 2025-2030 [D-dimer, PT/INR]

CHAPTER ELEVEN: MICROBIOLOGY PROCEDURES

• SCOPE
• INTRODUCTION
  • Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
• TYPES OF TESTS
  • ID/AST Automated Panels & Reagents
  • Manual Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
• GLOBAL SALES OF CONVENTIONAL IVD MICROBIOLOGY PRODUCTS
  • ID/AST Panels & Reagents
  • Blood Culture
  • Chromogenic Media
  • Rapid Microbiological Tests
  • Mass Spectrometry
    • Table 11-2: Conventional Microbiology Product Sales, by Type, 2025-2030 ($ million) [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
• PRICING TRENDS
  • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]

CHAPTER TWELVE: BLOOD GROUPING/TYPING PROCEDURES

• INTRODUCTION
  • Table 12-1: Blood Grouping/Typing Procedure Volumes, 2025-2030
  • Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
• TYPES OF TESTS
• BLOOD GROUPING/TYPING PRODUCT SALES
  • Table 12-2: Blood Grouping/Typing Product Sales, 2025-2030 ($ million)
• PRICING TRENDS
  • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2025-2030

CHAPTER THIRTEEN: HISTOLOGY/CYTOLOGY PROCEDURES

• SCOPE
• INTRODUCTION
  • Table 13-1: Histology/Cytology Procedural Volume, by Type, 2025-2030 [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
  • Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
• TYPES OF TESTS
  • Immunohistochemistry Tests
  • In Situ Hybridization Tests
  • Pap Tests
  • Traditional Non-Pap Stains
  • Circulating Tumor Cells
  • Flow Cytometry
• HISTOLOGY/CYTOLOGY IVD PRODUCT SALES
  • Table 13-2: Histology/Cytology Product Sales, by Type, 2025-2030 ($ million) [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
• PRICING TRENDS
  • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2025-2030

CHAPTER FOURTEEN: COMPANY PROFILES

• INTRODUCTION
  • Table 14-1: Revenues of Selected Top 20 IVD Companies, 2024 and estimated 2025 ($ million) [Abbott Diagnostics, Agilent, Becton Dickinson, bioMerieux, Bio-Rad Laboratories, Bruker - CALID, Danaher, Dexcom, Diasorin, Exact Sciences, Hologic, Illumina, Natera, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen]
• ABBOTT DIAGNOSTICS
  • Recent Revenue History
    • Table 14-2: Abbott Diagnostic Revenues, 2022-2024 ($ million)
    • Table 14-3: Abbott Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
• AGILENT TECHNOLOGIES
  • Recent Revenue History
    • Table 14-4: Agilent Revenues, 2022-2024 (million $)
• BECTON, DICKINSON AND COMPANY (BD)
  • Recent Revenue History
    • Table 14-5: BD Diagnostic Revenues, 2022-2024 (million $) FYE Sept 30
• BIOMERIEUX INC.
  • Recent Revenue History
    • Table 14-6: bioMerieux IVD Revenues, 2022-2024 (Euro million)
• BIO-RAD LABORATORIES, INC.
  • Recent Revenue History
    • Table 14-7: Bio-Rad Diagnostics Revenues, 2022-2024 ($ million)
• DANAHER CORPORATION
  • Recent Revenue History
    • Table 14-8: Danaher Global IVD Diagnostic Sales, 2022-2024 ($ million)
• DEXCOM
  • Recent Revenue History
    • Table 14-9: Dexcom IVD Diagnostic Sales, 2022-2024 ($ million)
• DIASORIN
  • Recent Revenue History
    • Table 14-10: Diasorin Revenues, 2022-2024 (million Euro )
• EXACT SCIENCES
  • Recent Revenue History
    • Table 14-11: Exact Sciences Revenues, 2022-2024 ($ million)
• HOLOGIC, INC.
  • Recent Revenue History
    • Table 14-12: Hologic Revenues, 2022-2024 ($ million)
• ILLUMINA
  • Recent Revenue History
    • Table 14-13: Illumina Diagnostics Revenues, 2022-2024 ($ million)
  • Recent Revenue History
    • Table 14-14: Mindray Revenue History, 2022-2024 (billion CNY)
• NATERA
  • Recent Revenue History
    • Table 14-15: Natera Revenue History, 2022-2024 ($ million)
• QUIDELORTHO CORPORATION
  • Recent Revenue History
    • Table 14-16: QuidelOrtho Revenue History, 2022-2024 ($ million)
    • Table 14-17: QuidelOrtho Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
• REVVITY
  • Table 14-18: Revvity Revenue History, 2022-2024 ($ million, estimated)
• ROCHE DIAGNOSTICS
  • Recent Revenue History
    • Table 14-19: Roche Diagnostics IVD Revenues, 2022-2024 (CHF million)
    • Table 14-20: Roche Diagnostic Revenues, by Segment, 2023-2024 (CHF million)
• SIEMENS HEALTHINEERS (SIEMENS)
  • Recent Revenue History
    • Table 14-21: Siemens Healthineers IVD Revenues, 2022-2024 (Euro million)
• SYSMEX CORPORATION
  • Recent Revenue History
    • Table 14-22: Sysmex IVD Revenues, 2022-2024 (FY March 31) (billions of yen)
    • Table 14-23: Sysmex Diagnostic Revenues, by Segment, 2022-2024 (billions of yen)
• THERMO FISHER SCIENTIFIC INC.
  • Recent Revenue History
    • Table 14-24: Thermo Fischer IVD Revenues, 2022-2024 ($ million)
• WERFEN
  • Recent Revenue History
    • Table 14-25: Werfen IVD Revenues, 2022-2024 (Euro billion)